Cardiovascular involvement in patients affected by acromegaly: An appraisal

被引:70
作者
Mosca, Susanna [1 ]
Paolillo, Stefania [1 ]
Colao, Annamaria [2 ]
Bossone, Eduardo [3 ]
Cittadini, Antonio [4 ]
Lo Iudice, Francesco [1 ]
Parente, Antonio [1 ]
Conte, Sirio [1 ]
Rengo, Giuseppe [5 ]
Leosco, Dario [4 ]
Trimarco, Bruno [1 ]
Filardi, Pasquale Perrone [1 ]
机构
[1] Univ Naples Federico II, Dept Adv Biomed Sci, I-80131 Naples, Italy
[2] Univ Naples Federico II, Endocrinol Sect, Dept Mol & Clin Endocrinol & Oncol, I-80131 Naples, Italy
[3] Univ Hosp Scuola Med Salernitana, Dept Cardiol & Cardiac Surg, Salerno, Italy
[4] Univ Naples Federico II, Dept Internal Med Cardiovasc & Immunol Sci, I-80131 Naples, Italy
[5] Salvatore Maugeri Fdn, Inst Telese Terme BN, IRCCS, Div Cardiol, San Giovanni Rotondo, Italy
关键词
Acromegaly; Acromegalic cardiomyopathy; GH/IGF-I excess; Premature atherosclerosis; GROWTH-FACTOR-I; SOMATOSTATIN ANALOG OCTREOTIDE; LEFT-VENTRICULAR HYPERTROPHY; HORMONE RECEPTOR ANTAGONIST; LONG-TERM; CARDIAC-PERFORMANCE; RISK-FACTORS; GLUCOSE-HOMEOSTASIS; LATE POTENTIALS; TRANSSPHENOIDAL SURGERY;
D O I
10.1016/j.ijcard.2012.11.109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular complications are frequent in acromegalic patients. Several studies reported increased prevalence of traditional cardiovascular risk factors and early development of endothelial dysfunction and of structural vascular alterations, with subsequent increased risk of coronary artery disease. Furthermore, chronic exposure to high levels of GH and IGF-I leads to the development of the so called "acromegalic cardiomyopathy", characterized by concentric biventricular hypertrophy, diastolic dysfunction and, additionally, by progressive impairment of systolic performance leading to overt heart failure. Cardiac valvulopathies and arrhythmias have also been documented and may concur to the deterioration of cardiac function. Together with strict control of cardiovascular risk factors, early control of GH and IGF-I excess, by surgical or pharmacological therapy, has been reported to ameliorate cardiac and metabolic abnormalities, leading to a significant reduction of left ventricular hypertrophy and to a consistent improvement of cardiac performance. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:1712 / 1718
页数:7
相关论文
共 83 条
[1]   Acromegaly per se does not increase the risk for coronary artery disease [J].
Akutsu, Hiroyoshi ;
Kreutzer, Juergen ;
Wasmeier, Gerald ;
Ropers, Dieter ;
Rost, Christian ;
Moehlig, Matthias ;
Wallaschofski, Henri ;
Buchfelder, Michael ;
Schoefl, Christof .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2010, 162 (05) :879-886
[2]   LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy [J].
Arosio, M ;
Sartore, G ;
Rossi, CM ;
Casati, G ;
Faglia, G ;
Manzato, E .
ATHEROSCLEROSIS, 2000, 151 (02) :551-557
[3]   Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients [J].
Baldelli, R ;
Ferretti, E ;
Jaffrain-Rea, ML ;
Iacobellis, G ;
Minniti, G ;
Caracciolo, B ;
Moroni, C ;
Cassone, R ;
Gulino, A ;
Tamburrano, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :527-532
[4]   Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment [J].
Baldelli, Roberto ;
Battista, Claudia ;
Leonetti, Frida ;
Ghiggi, Maria-Rosaria ;
Ribaudo, Maria-Cristina ;
Paoloni, Antonella ;
D'Amico, Eugenio ;
Ferretti, Elisabetta ;
Baratta, Roberto ;
Liuzzi, Antonio ;
Trischitta, Vincenzo ;
Tamburrano, Guido .
CLINICAL ENDOCRINOLOGY, 2003, 59 (04) :492-499
[5]   Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant [J].
Barkan, AL ;
Burman, P ;
Clemmons, DR ;
Drake, WM ;
Gagel, RF ;
Harris, PE ;
Trainer, PJ ;
van der Lely, AJ ;
Vance, ML .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5684-5691
[6]   Impairment in Flow-Mediated Vasodilatation of the Brachial Artery in Acromegaly [J].
Baykan, Merih ;
Erem, Cihangir ;
Gedikli, Oemer ;
Hacihasanoglu, Arif ;
Erdogan, Turan ;
Kocak, Mustafa ;
Kaplan, Sahin ;
Korkmaz, Levent ;
Celik, Suekrue .
MEDICAL PRINCIPLES AND PRACTICE, 2009, 18 (03) :228-232
[7]  
BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327
[8]   Cardiovascular Risk Factors in Patients with Uncontrolled and Long-Term Acromegaly: Comparison with Matched Data from the General Population and the Effect of Disease Control [J].
Berg, Christian ;
Petersenn, Stephan ;
Lahner, Harald ;
Herrmann, Burkhard L. ;
Buchfelder, Michael ;
Droste, Michael ;
Stalla, Guenter K. ;
Strasburger, Christian J. ;
Roggenbuck, Ulla ;
Lehmann, Nils ;
Moebus, Susanne ;
Joeckel, Karl-Heinz ;
Moehlenkamp, Stephan ;
Erbel, Raimund ;
Saller, Bernhard ;
Mann, Klaus .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (08) :3648-3656
[9]   GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly [J].
Boero, L. ;
Manavela, M. ;
Merono, T. ;
Maidana, P. ;
Gomez Rosso, L. ;
Brites, F. .
CLINICAL ENDOCRINOLOGY, 2012, 77 (04) :579-585
[10]   Increased oxidized low density lipoprotein associated with high ceruloplasmin activity in patients with active acromegaly [J].
Boero, L. ;
Cuniberti, L. ;
Magnani, N. ;
Manavela, M. ;
Yapur, V. ;
Bustos, M. ;
Gomez Rosso, L. ;
Merono, T. ;
Marziali, L. ;
Viale, L. ;
Evelson, P. ;
Negri, G. ;
Brites, F. .
CLINICAL ENDOCRINOLOGY, 2010, 72 (05) :654-660